NSPR News and Press, InspireMD Inc. From 03/30/23

- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) f...

2023-03-29 13:10:54 ET InspireMD ( NASDAQ: NSPR ) is scheduled to announce Q4 earnings results on Thursday, March 30th, before market open. The consensus EPS Estimate is -$0.84 (-58.5% Y/Y) and the consensus Revenue Estimate is $1M (-27.5% Y/Y). For further details s...

2023-03-29 10:28:48 ET Major earning expected before the bell on Thursday include: EVgo ( EVGO ) Imunon ( IMNN ) Li-Cycle Holdings ( LICY ) Nano Dimension ( NNDM ) PetroChina (PTR) For further details see: Notable earnings before Thursday's open

2023-03-20 08:20:25 ET InspireMD ( NASDAQ: NSPR ) promoted Andrea Tommasoli to CO; he formerly served as SVP of Global Sales & Marketing since joining the company in November 2020. "Andrea has been instrumental in expanding the footprint of CGuard EPS across ...

TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served ...

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, an...

TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North Ame...

TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days of Carotid Stenting,” which will feature leading mul...

TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being ...

InspireMD, Inc. (NSPR) Q3 2022 Earnings Conference Call November 8, 2022 08:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partner...